Viva La Revolución: Options to Combat Hepatitis C
|
|
- Laureen Paul
- 5 years ago
- Views:
Transcription
1 Viva La Revolución: Options to Combat Hepatitis C David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After attending this presentation, learners will be able to: List the available drugs and regimens for treating hepatitis C and their viral targets Describe the efficacy of treatments, by virus genotype, for initial therapy and retreatment Slide 2 of 33 SVR (%) 2 Slide 3 of 33 HCV Therapeutics Timeline You are here BILN-261 BoceprevirTelaprevir Phase 1b SOF/LDV Consensus IFN In vitro PrO-D EBR/GZR GLE/PIB Peg-IFNa-2bHCV replication 1989 HCV Vaccine?? identified IFN a-2b Sofosbuvir IFN a-2a HCV replicons Peg-IFNa-2a Simeprevir Daclatasvir (US) IFN a-2b + RBV Peg-IFNa-2ain HCV/HIVDaclatasvir (EU) Relative misery
2 Overview of HCV life-cycle and antiviral targets NS5A Inhib NS3 Inhib NS5B Inhib Slide 4 of 33 Georgel et al. Trends in Molecular Medicine 16(21) Moradpour D. Nat Rev 27. Approved HCV antiviral drugs/regimens Approved in 217 SOF/ VEL/VO X G/P Slide 5 of 33 SOF / LDV SOF / VEL SOF DC V IFN-free Treatment Options pre-217 SOF SM V EBR/ GZR OBV/ RBV PTV/r DSV SOF RBV Characteristics of Direct Acting Antivirals (DAAs) Simeprevir Paritaprevir Drug Class Activity Potency GT 1, 4 Resistance Barrier Low (1a<1b) Slide 6 of 33 Grazoprevir Voxilaprevir Glecaprevir Daclatasvir NS3 PI GT 1, 4 & 6 (3) GT 1-6 GT 1-6 Ledipasvir GT 1, 4 & 6 Ombitasvir NS5A Elbasvir GT 1,4 & 6 Velpatasvir Pibrentasvir Sofosbuvir NS5B Nucleotide GT 1-6 GT 1-6 High High High Moderate High Low (1a<1b) Moderate Very high Very High
3 In vitro activity: old vs. new NS3 PI (nm) GT1a GT1b GT2a GT3a GT4a GT6a Paritaprevir a Simeprevir NA NA Asunaprevir NA NA Grazoprevir Glecaprevir a Voxilaprevir NS5A (pm) GT1a GT1b GT2a GT2b GT3a GT4a GT5a GT6a Ombitasvir Daclatasvir , NA Ledipasvir , 16, 168, Elbasvir Velpatasvir Pibrentasvir Ruzasvir Slide 7 of 33 NS5B nucleoside polymerase inhibitors have consistent pangenotypic acitivity (sofosbuvir, uprifosbuvir) New approval in 217: Glecaprevir/Pibrentasivr Slide 8 of What: NS3 protease inhibitor plus NS5A inhibitor 2. Pangenotypic and activity against RASs 8 week option for non-cirrhotic patients (all GT1, 2, 4-6; GT3 only naïve) High efficacy in GT3 12 week treatment duration with cirrhosis 16 weeks if treatment experienced 3. Genotyping still required for treatment experienced 4. Drug-interaction potential Statins- atorvastatin not recommended Acid reducing agents lower exposure; NO clear impact on outcomes 5. Caution: Safety unknown in decompensated cirrhosis (CTP-B/C). Till data available, should be avoided as with all PI-containing HCV regimens New approval in 217: Sofosbuvir/velpatasvir/voxilaprevir Slide 9 of What: NS5B nucleoside plus NS5A inhibitor plus NS3 protease inhibitor 2. Pangenotypic and activity against RASs 8 weeks did not meet non-inferiority criteria compared to SOF/VEL for 12 weeks Driven by lower response in GT1a High efficacy in GT3 8 week treatment duration possible with cirrhosis 3. May require genotyping to optimize management 4. Primary role likely in DAA failures- high efficacy, no demonstrable impact of resistance 5. Caution: Safety unknown in decompensated cirrhosis (VOX; CTP-B/C). SOF metabolite accumulation in ESRD (egfr <3ml/min) Till data available, should be avoided as with all PI-containing HCV regimens Caution in severe renal impairment
4 ARS Question 1: Eight weeks of LDV/SOF is not recommended for which patient population with GT1 and an HCV RNA <6 million? (AASLD/IDSA Guidelines) 1. Patients without cirrhosis 2. Black patients 3. Female patients 4. Male patients 5. Genotype 1a subtype Slide 1 of 33 SOF/LDV: 8 vs. 12 weeks for treatment naïve GT1 N=216 N=215 N=216 SOF/LDV SOF/LDV SOF/LDV/r 8 Weeks Cirrhosis excluded Relapses 4-5% in 8 week arms 2/23 in 8 week arms 1% in 12 week arm Post-hoc analyses HCV RNA <6 million 2% relapse in 8 and 12 weeks arms 99% SVR women 91% SVR Black 12 ION wk 8wk HCV Guidelines 8 week recommendation Non-black HIV uninfected HCV RNA <6 million Slide 11 of 33 Impact of Baseline NS5A RAVs in Pts With GT1a HCV Treated With EBR/GZR Analysis of pts with GT1a HCV treated with GZP/EBR in phase II/III trials (naive/relapsers) Population Sequencing Next-Generation Sequencing (1% Level) EBR RAVs NS5A Class RAVs EBR RAVs NS5A Class RAVs No RAVS: 414/438 (95%) No RAVS: No RAVS: No RAVS: 5% 432/438 2% 396/439 1% 289/439 35% (8%) (9%) (65%) Slide 12 of Patients without 6 RAVs Patients with RAVs / 14/ 345/ 74/ 389/ 31/ 284/ 136/ EBR RAVs NS5A RAVs EBR RAVs NS5A RAVs Population Sequencing Next Generation Sequencing Jacobson I, et al. AASLD 215. Abstract LB-22.
5 GZR/EBR Efficacy in GT1a HCV: Resistance is all that matters! Analysis of PEP* of TN pts with GT1a HCV treated with GZP/EBR in phase II/III trials Multivariable logistic regression model eor (95% CI) P value *PEP = pooled efficacy population. Slide 13 of 33 Zeuzem S, et al. AASLD 215. Abstract 7. Integrated analysis of G/P in non-cirrhotics ITT Pooled analysis across phase 2/3 studies G/P 8 wk vs 12 wk Non-cirrhotic GT3 were also treatment naïve mitt (exclude non-virologic failures) 1/13 virologic failures were GT3.6% discontinued prematurely (same in 8 and 12 wk arms) Slide 14 of 33 Pol S. SAT-233. EASL 217. EXPEDITION-I: GT1, 2, 4-6 with cirrhosis 25% Treatment experienced 8% SOF experienced 2% with PLT <1, Slide 15 of 33 1 VF: Y93N at baseline Y93N + Q3R + H58D
6 ASTRAL-1: SOF/VEL for 12 weeks Slide 16 of weeks of SOF/VEL a 1b Genotype virologic failures: 1a, TN, NC, IL28 CT with Q3R 1b, TE, Cirr, IL28 TT with Q3R/L31M SVR with baseline NS5A RASs*: 99% (255/257) *RASs at >1%, all genotypes 32% treatment experienced (99% SVR12); 19% cirrhosis (99% SVR12) Slide 17 of 33 Genotype 1 treatment naïve Recommended vs Alternative Treatment naïve 1a 1b LDV/SOF GLE/PIB EBR/GZR SOF/VEL PTV/r/OBV +DSV 8 $ - 8WKS Cirrhosis * RASs: 16WKS+R * RASs: 16WKS+R +R 24WKS+R 8WKS Cirrhosis $- additional criteria apply R=weight-based Ribavirin *RAS testing recommended-rass= EBR specific NS5A RAVs (28, 3, 31, 93) Slide 18 of 33 Genotype 1 treatment experienced Recommended vs Alternative Interferon+RBV LDV/SOF GLE/PIB EBR/GZR SOF/VEL 1a 1b Cirrhosis Cirrhosis +R # 24WKS # 8WKS * RASs: 16WKS+R * RASs: 16WKS+R PTV/r/OBV +DSV +R 24WKS+R 8WKS +R 24WKS # Consider RAS testing. *RAS testing recommended-rass= EBR specific NS5A RAVs (28, 3, 31, 93)
7 ARS Question 2: NS5A resistance testing should be considered in which population infected with GT3 HCV prior to use of SOF/VEL? 1. Treatment experienced (IFN) patients without cirrhosis 2. Treatment naïve patients without cirrhosis 3. SOF/DCV experienced patients 4. Treatment experienced (IFN) patients with cirrhosis Slide 19 of 33 G/P in GT3 treatment naïve patients without cirrhosis ENDURANCE-3 Slide 2 of 33 2% VF 4% VF Integrated analysis of 8 vs. 12 weeks in GT3 8 weeks N=28 12 weeks N=294 Slide 21 of 33
8 Genotype 2/3 treatment naïve Recommended Treatment naïve 2 SOF /VEL GLE /PIB 8WKS Cirrhosis 3 Cirrhosis # 8WKS Slide 22 of 33 R=weight-based Ribavirin # Consider RAS testing ASTRAL-3: SOF/VEL for genotype 3 infection Wk Wk 12 Wk 24 N = 277 N = 275 SOF/VEL SOF + RBV SVR12 SVR12 Treatment Experienced Slide 23 of TE Cirrhotic TE Cirr SOF/VEL SOF/RBV Foster GR, et al. N Engl J Med. 215;373: G/P in treatment experienced GT3 42 (46%) of TE were SOF experienced Slide 24 of 33
9 C-ISLE: SOF + EBR/GZR for GT3 with cirrhosis naïve experienced 68% male Mean TE: 25.4 kpa 24% PLT <1, Slide 25 of 33 Slide 26 of 33 IFN+RBV (+/- SOF) Genotype 2/3 TE Recommended vs Alternative GLE/ PIB SOF/ VEL EBR/ GZR + SOF SOF/VEL /VOX 2 NC 8WKS (12 if SOF) Cirr NC 16WKS # (not if SOF exposed) -- (if Y93H) Cirr 16WKS +R R=weight-based Ribavirin # Consider RAS testing Triple DAA therapy for re-treatment 1 Regimen: SOF/VEL/VOX for 12 weeks POLARIS-1 (n=263) POLARIS-4 (n=182) NS5A experienced 46% cirrhosis NO NS5A exposure 46% cirrhosis 97% SVR vs 9% SOF/VEL /11 GT1a non-svr 2 LTFU 1 relapse 1 BT (non-compliance) 2 All No Cirrhosis Cirrhosis SVR12: 96% GT1a; 1% GT1b; 95% GT3 Slide 27 of 33 No cirrhosis Cirrhosis SOF/VEL/VOX: 98% GT1a; 96% GT1b; 94% GT3 Bourliere M. NEJM 217. SOF/VEL: 89% GT1a; 95% GT1b; 85% GT3
10 GLE/PIB for DAA experienced patients: MAGELLAN-I (parts 1 and 2) Part 1: 12 weeks GLE/PIB 86% (19/22) SVR12; 95% (19/2) SVR mitt 1 VF: PrOD experience with NS3 (Y56H, D168A/T) and NS5A (M28V, Q3R, H58C)RASs Part 2: 12 vs. 16 wks GLE/PIB PI NS5A both NS3 RASs NS5A RASs NS3+5A RASs GT1 and 4 DAA experienced PI: 3% NS5A: 37% PI+NS5A: 29% 3% cirrhosis Slide 28 of 33 PoordadF. Hepatology 217. PoordadF. PS-156. EASL 217 DAA experienced: What do the labels say? Prior treatment SOF/VEL/VOX GLE/PIB GT1 NS5A (+/- SOF) 12 (also 2-6) 16 GT1 NS3 (+/- SOF) 12 (1a only) 12 GT1-6 NS3+NS5A 12 NR GT3 SOF (no NS5A) AASLD/IDSA Guidelines: GT3 NS5A-experienced with compensated cirrhosis Slide 29 of 33 Reminder: HCV PIs (including VOX and GLE) are either not recommended or contraindicated in CTP B/C cirrhosis Options for patients with end-stage renal disease 1 GT1: EBR/GZR 12 weeks GT 1-6: G/P 12 wks 42% TE, 2% F per protocol 6 4 ITT Overall No Yes 4 5 No Yes (n=116) (n=11) (n=6) (n=22) (n=94) (n=29) (n=87) Cirrhosis CKD Stage Dialysis 94% SVR12 in ITT analysis Slide 3 of /14 CKD 4/5 1% SVR mitt
11 Treatment of HCV in HIV/HCV Coinfection Same Regimens, Same Efficacy as in HCV Monoinfection Patients With SVR12, % SOF/VEL ELB/GRZ LDV/SOF GLE/PIB HIV/HCV HCV Slide 31 of 33 Slide 32 of 33 Take home points Tremendous advances in antiviral treatment of HCV have been realized in the last 5 years SVR >95% is attainable in all populations with 8-12 weeks of therapy From a treatment efficacy standpoint there are no more special populations There is a very limited role for resistance testing or the use of ribavirin Diagnosis, access and coverage limitations are now the most significant barriers to HCV cure Question-and-Answer Remember to raise your hand and wait until you have the microphone before you ask your question we are recording! Slide 33 of 33
Cases: Management of Hepatitis C in Prior Treatment Failure
Cases: Management of Hepatitis C in Prior Treatment Failure David L. Wyles, MD Professor of Medicine University of Colorado Chief, Division of Infectious Disease Denver Health Learning Objectives After
More informationDirect-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD
Direct-acting Antiviral (DAA) Regimens in Late-stage Development: Which Patients Should Wait? Fred Poordad, MD The HCV Lifecycle: Multiple Targets Polymerase Inhibitors Protease Inhibitors NS5A Inhibitors
More informationHCV Resistance Clinical Aspects. Sanjay Bhagani Royal Free Hospital/UCL London
HCV Resistance Clinical Aspects Sanjay Bhagani Royal Free Hospital/UCL London DAAs in 2018, and beyond % patients % patients Changing characteristics of patients treated with DAA over time Prospective,
More information2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients
2017 Bruce Lucas Hepatology and Liver Transplant Symposium October 13th 2017 Management of Hepatitis C in Pre- and Post-Transplant Patients Jens Rosenau, MD Associate Professor of Medicine Acting Director
More informationDisclosures. Advanced HCV management. Overview. Renal failure 1/10/2018. Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH
Disclosures Advanced HCV management Annie Luetkemeyer, MD Division of HIV, ID and Global Medicine ZSFG, UCSF Research Grant support to UCSF from AbbVie Gilead Merck Proteus NIH Overview Renal failure Acute
More informationManagement of HCV in Prior Treatment Failure
Management of HCV in Prior Treatment Failure Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Boston, Massachusetts Learning Objectives After attending this presentation, learners
More information10/21/2016. David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? David L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado FORMATTED: 1/3/16
More informationDavid L. Wyles, MD Chief, Division of Infectious Disease Denver Health Medical Center Denver, Colorado
FORMATTED: 1/3/16 Drug Resistance-Associated Variants in Hepatitis C Virus Infection: Hype or Help? Atlanta, Georgia: October 2, 216 David L. Wyles, MD Chief, Division of Infectious Disease Denver Health
More informationHCV in 2017: New Therapies and New Opportunities. Presentation prepared by: Date prepared: OBJECTIVES
Project ECHO HCV Collaborative HCV in 217: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College of Pharmacy University
More informationHepatitis C Genotypes
9/2/21 OBJECTIVES Project ECHO HCV Collaborative HCV in 21: New Therapies and New Opportunities Paulina Deming, PharmD Assistant Director Hepatitis C Programs, ECHO Institute Associate Professor College
More informationHepatitis C Update: What s New in 2017
Hepatitis C Update: What s New in 2017 Cody A. Chastain, MD Assistant Professor of Medicine Viral Hepatitis Program Division of Infectious Diseases Vanderbilt University Medical Center Cody.a.Chastain@Vanderbilt.edu
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationCurrent HCV Treatment by Genotype
Current HCV Treatment by Genotype Ari Bunim, MD Assistant Professor Clinical Medicine Weill Cornell Medical College Clinical Director of Hepatology New York-Presbyterian/Queens Objectives To understand
More informationHEPATITIS C: UPDATE AND MANAGEMENT
HEPATITIS C: UPDATE AND MANAGEMENT José Franco, MD Professor of Medicine Associate Dean for Educational Improvement Associate Director, Kern Institute STAR Center Director José Franco, MD Disclosures I
More informationKristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York
Newly Approved Hepatitis C Virus Drugs: Approach to Initial Therapy Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, New York Learning Objectives After attending this presentation,
More informationCurrent HCV Treatment by Genotype Ira M. Jacobson, MD
Current HCV Treatment by Genotype Ira M. Jacobson, MD Director of Hepatology NYU School of Medicine Objectives To understand the prevalence of HCV and distribution of HCV genotypes Describe the HCV lifecycle
More informationHCV therapy : Clinical case
HCV therapy : Clinical case PHC 2018 Paris January 14th, 2018 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures Professor Asselah
More informationHepatitis C Introduction and Overview
Hepatitis C Introduction and Overview Michael S. Saag, MD Professor of Medicine Associate Dean of Global Health Director, Center for AIDS Research University of Alabama at Birmingham Birmingham, Alabama
More informationHCV Treatment of Genotype 1: Now and in the Future
HCV Treatment of Genotype 1: Now and in the Future Bruce R. Bacon, MD, FACG James F. King, MD Endowed Chair in Gastroenterology Professor of Internal Medicine Co-Director of the Abdominal Transplant Program
More informationDebate: Do We Need More HCV Drugs Con Standpoint
Debate: Do We Need More HCV Drugs Con Standpoint 18 th Antivirals PK Workshop, Friday 16 th June 2017, Chicago Jürgen Rockstroh Department of Medicine I University Hospital Bonn, Bonn, Germany Conflict
More information5/10/2016. Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients. HCV life-cycle and antiviral targets
5/1/216 Management of Hepatitis C Virus Genotype 1 and 4 Treatment-Naive and Treatment-Experienced Patients David L. Wyles, MD Associate Professor of Medicine University of California San Diego La Jolla,
More informationHCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London
HCV Treatment Failure: What Next? Dr Ashley Brown, Imperial College Healthcare NHS Trust, London European HIV Hepatitis Co-infection Conference QEII Conference Centre 10 th December 2015 Dr Ashley Brown
More informationGenotype 1 HCV in 2016: Clinical Decision Making in a Time of Plenty
Genotype 1 HCV in 216: Clinical Decision Making in a Time of Plenty Ira M. Jacobson, MD Chair, Department of Medicine Mount Sinai Beth Israel Senior Faculty and Vice-Chair, Department of Medicine Icahn
More informationTreatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos
Treatment of HCV infection in daily clinical practice. Which are the optimal options for Genotypes 2 and 3? Jiannis Vlachogiannakos Associate Professor of Gastroenterology Academic Department of Gastroenterology
More informationHepatitis C in Special Populations
Hepatitis C in Special Populations David E. Bernstein, MD, FACG Vice Chairman of Medicine for Clinical Trials Chief, Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases Northwell Health
More informationSaeed Hamid, MD Alex Thompson, MD, PhD
Saeed Hamid, MD Alex Thompson, MD, PhD 1 We will review some top line data from EASL Majority of the time discussing how the data affects daily practice 2 Grazoprevir (GZR; MK-5172) + Elbasvir (EBR; MK-
More informationHCV Infection: EASL Clinical Practice Guidelines Francesco Negro University Hospital Geneva Switzerland
HCV Infection: EASL Clinical Practice Guidelines 2016 Francesco Negro University Hospital Geneva Switzerland Panel Codinat: Jean-Michel Pawlotsky Panel: Alessio Aghemo David Back Geoffrey Dusheiko Xavier
More informationUpdates on the AASLD/IDSA HCV Guidance
Updates on the AASLD/IDSA HCV Guidance Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University School of Medicine Durham, North Carolina Learning Objectives After attending this presentation,
More informationSelecting HCV Treatment
Selecting HCV Treatment Caveats Focus on treatment selection for genotypes 1, 2, and 3. Majority of US population infected with GT 1, 2, or 3 GT 4 treatment closely reflects GT 1 treatment GT 5 and 6 are
More informationShorter Durations and Pan-genotypic Regimens The Final Frontier. Professor Greg Dore
Shorter Durations and Pan-genotypic Regimens The Final Frontier Professor Greg Dore Disclosures Funding and speaker fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences and Merck Efficacy Evolution
More informationHow to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France
How to optimize treatment in G3 patients? Jérôme GOURNAY, MD Hépatologie Centre Hospitalier Universitaire de Nantes France Paris Hepatitis Conference, January 12, 2016 Disclosures I have received funding
More informationHIV-HCV Co-Infection in Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School
HIV-HCV Co-Infection in 2018 Shobha Swaminathan, MD Associate Professor of Medicine Rutgers New Jersey Medical School AASLD/IDSA and DHHS Guidance: HIV/HCV Coinfection All pts with HIV should be screened
More informationWhat do we need to know about RAVs clinically?
14 th European HIV & Hepatitis Workshop Rome, 25-27 May, 2016 What do we need to know about RAVs clinically? Stefan Zeuzem, MD University of Frankfurt Germany Background Resistance associated variants
More informationHepatitis C: The New World of Treatment
Hepatitis C: The New World of Treatment Aban 1395, NIOC Hospital Shahin Merat, M.D. Professor of Medicine Digestive Disease Research Institute Tehran University of Medical Sciences 1 Drugs NS5B polymerase
More informationCases: Initial Treatment of Hepatitis C
Cases: Initial Treatment of Hepatitis C Kristen Marks, MD Assistant Professor of Medicine Weill Cornell Medical College New York, New York Off-Label Warning I will discuss the following off-label use in
More informationCurrent trends in CHC 1st genotype treatment
Current trends in CHC 1st genotype treatment Tarik Asselah MD, PhD Professor of Medicine Hepatology, Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France Disclosures Employee of Paris Public University
More informationHCV Update from AASLD 2016
HCV Update from AASLD 2016 Ahmed Elsharkawy Consultant Hepatologist QE Birmingham Secretary and Chair-Elect of BVHG BHIVA/BVHG Feedback Meeting November 2016 Speaker Name Ahmed Elsharkawy Statement Speaking
More informationHCV Treatment Options in 2017/2018: What s Here and What s Coming Soon
HCV Treatment Options in 2017/2018: What s Here and What s Coming Soon Supported by educational grants from AbbVie; Bristol-Myers Squibb; Gilead Sciences; Janssen Therapeutics; Merck & Co., Inc; and ViiV
More informationOn Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018
On Target for Hepatitis C Elimination: Direct Acting Antiviral Agents in 2018 Trana Hussaini, PharmD Pharmacotherapy Specialist in Liver Transplantation, VGH Clinical Assistant Professor, Faculty of Pharmaceutical
More informationExpert Perspectives: Best of HCV from EASL 2015
Best of HCV from EASL 2015 Expert Perspectives: Best of HCV from EASL 2015 Saeed Hamid, MD Alex Thompson, MD, PhD This activity is supported by educational grants from AbbVie, Bristol-Myers Squibb, and
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationHepatitis C in 2018: From Evolution to Revolution
Hepatitis C in 218: From Evolution to Revolution Arthur Y. Kim, MD Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Massachusetts General Hospital Boston, Massachusetts
More informationA treatment revolution: current management for chronic HCV
A treatment revolution: current management for chronic HCV Ray Chung, M.D. Director of Hepatology and Liver Center Kevin and Polly Maroni Research Scholar Massachusetts General Hospital Disclosures Research
More informationNeed to Assess HCV Resistance to DAAs: Is it Useful and When?
Need to Assess HCV Resistance to DAAs: Is it Useful and When? Stéphane Chevaliez French National Reference Center for Viral Hepatitis B, C and delta Department of Virology & INSERM U955 Henri Mondor Hospital
More informationA One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran
A One-day Scientific Conference: Updates on Hepatitis C Treatments along with Consensus on Management of Hepatitis C in Iran Teheran, 22 July 2016 Massimo Colombo Treatment of HCV genotype 1 & 4 with DAAs
More informationHCV Treatment in 2016: Genotypes 1, 2, and 3. Cody A. Chastain, MD October 12, 2016
HCV Treatment in 2016: Genotypes 1, 2, and 3 Cody A. Chastain, MD October 12, 2016 Disclosures I have no financial disclosures. Caveats I will only discuss treatment of GT 1-3. Majority of US population
More informationTREATMENT OF GENOTYPE 2
Treatment of Genotype 2, 3,and 4 David E. Bernstein, MD, FACG Advisory Committee/Board Member: AbbVie Pharmaceuticals, Gilead, Merck, Janssen Consultant: AbbVie Pharmaceuticals, Bristol-Myers Squibb, Gilead,
More informationNew Antivirals for Hep C in Context of HIV: Vosevi and Mavyret
New Antivirals for Hep C in Context of HIV: Vosevi and Mavyret John Scott, MD, MSc, FIDSA November 16, 2017 This presentation is intended for educational use only and does not in any way constitute medical
More information10/21/2016. Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina. Learning Objectives
A Crash Course on the AASLD/IDSA Hepatitis C Virus Infection Treatment Guidelines: What s New Susanna Naggie, MD, MHS Associate Professor of Medicine Duke University Durham, North Carolina FORMATTED: 1/3/16
More informationTreatment of HCV : 100 % cure?
Treatment of HCV : % cure? PHC 8 PARIS January 5th, 8 Tarik Asselah (MD, PhD) Professor of Medicine Hepatology, Chief ISERM UMR 49, Hôpital Beaujon, Clichy, France. PHC 8 - www.aphc.info Disclosures Employee
More informationHepatitis B and Hepatitis C Virus in non-liver Transplant Recipients. Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London
Hepatitis B and Hepatitis C Virus in non-liver Transplant Recipients Karim Qumosani MD, FRCPC, ABIM, MdMEd Multi-organ Transplant Unit, London Financial Disclosures Research Grants Merck, Gilead, Abbvie,
More informationWhat is the Optimized Treatment Duration? To Overtreat versus Undertreat. Nancy Reau, MD Associate Professor of Medicine University of Chicago
What is the Optimized Treatment Duration? To Overtreat versus Undertreat Nancy Reau, MD Associate Professor of Medicine University of Chicago Learning Objectives: 1. Discuss patient populations appropriate
More informationUniversal HCV treatment: Strategies for simplification
Universal HCV treatment: Strategies for simplification PARIS HEPATOLOGY CONFERENCE 3 January 217 Tarik Asselah (MD, PhD) Hepatology & Chief INSERM UMR 1149, Hôpital Beaujon, Clichy, France. Disclosures
More informationTHE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE
THE THERAPEUTIC REVOLUTION THAT TRANSFORMED CHRONIC HEPATITIS C TO A CURABLE DISEASE MARIA SCHINA CONSULTANT PHYSICIAN INTERNAL MEDICINE AND HEPATOLOGY ATHENS EUROCLINIC 10 th INTERNATIONAL CONGRESS OF
More informationWhat Should We Do With Difficult to Treat HCV Populations?
What Should We Do With Difficult to Treat HCV Populations? Norah Terrault, MD Professor of Medicine and Surgery Director, Viral Hepatitis Center University of California San Francisco Disclosures Norah
More informationIs HCV drug resistance an issue?
Is HCV drug resistance an issue? 5TH ASIAN CONFERENCE ON HEPATITIS&AIDS NANJING, CHINA 28-29 MAY 2016 FROM BASIC SCIENCE TO CLINICAL PRACTIC Jürgen Kurt Rockstroh Department of Medicine I, University Hospital
More informationSTATE OF THE ART Update: Treatment Options 2016 Mark Sulkowski, MD
Housekeeping Please turn off or silence cell phones. Restrooms are located on this floor. Make a left out of the ballroom foyer and the men s room is on your left. The ladies room is across from the elevators
More informationPatients with compensated cirrhosis: how to treat and follow-up
Patients with compensated cirrhosis: how to treat and follow-up Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Universitätsklinikum Leipzig Leber- und Studienzentrum
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationInitial Treatment of HCV G Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona
Initial Treatment of HCV G1 2016 Hugo E. Vargas, MD Professor of Medicine Medical, Director Office of Clinical Research Mayo Clinic Arizona Disclosure Information Disclosure Information Dr. Vargas receives
More informationUpdate on Hepatitis C. Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017
Update on Hepatitis C Francesco Negro Hôpitaux Universitaires de Genève Berne, November 15, 2017 The global prevalence of HCV was 1 0% (95% uncertainty interval 0 8 1 1) in 2015: 71 1 million (62 5 79
More informationHepatitis C: New Therapies in
Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and
More informationBaseline and acquired viral resistance to DAAs: how to test and manage
Baseline and acquired viral resistance to DAAs: how to test and manage Round table discussion by Marc Bourliere, Robert Flisiak, Vasily Isakov, Mark Sulkowsky & Konstantin Zhdanov Prevalence of baseline
More informationVirological tools for hepatitis C: re-treatment and resistance. Joop Arends Will Irving. by author
Virological tools for hepatitis C: re-treatment and resistance Joop Arends Will Irving Disclosures Joop Arends Advisory board: Gilead, Abbvie, Janssen, MSD, BMS (research) grants: Abbvie, BMS, MSD and
More informationTreating Hepatitis C Virus (HCV) Infection
Slide 1 of 42 Treating Hepatitis C Virus (HCV) Infection Susanna Naggie, MD, MHS Associate Professor of Medicine Duke Clinical Research Institute Durham, North Carolina Slide 3 of 42 Learning Objectives
More informationHIV/HCV Coinfection: Why It Matters and What To Do About It. Cody A. Chastain, MD 10/26/16
HIV/HCV Coinfection: Why It Matters and What To Do About It Cody A. Chastain, MD 10/26/16 Disclosures I have no relevant financial disclosures. Objectives At the end of this lecture, the learner will be
More informationHCV resistance testing in clinical practice. Daniel Bradshaw Virus Reference Department National Infection Service Public Health England
HCV resistance testing in clinical practice Daniel Bradshaw Virus Reference Department National Infection Service Public Health England Declaration of Interests Dan Bradshaw has received personal grants
More informationHCV Management in Decompensated Cirrhosis: Current Therapies
Treatment of Patients with Decompensated Cirrhosis and Liver Transplant Recipients Paul Y. Kwo, MD, FACG Professor of Medicine Gastroenterology/Hepatology Division Stanford University email pkwo@stanford.edu
More informationAntiviral treatment in Unique Populations
Antiviral treatment in Unique Populations Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Unique HCV Populations HIV/HCV co-infected
More informationHCV Treatment in 2016
HCV Treatment in 2016 Hugo E. Vargas, MD Professor of Medicine Mayo College of Medicine Medical Director, Clinical Trials Office Vice Chair, Department of Research Educational Goals Caveats: Cannot cover
More informationTreatment of Unique Populations Raymond T. Chung, MD
Treatment of Unique Populations Raymond T. Chung, MD Director of Hepatology and Liver Center Vice Chief, Gastroenterology Kevin and Polly Maroni Research Scholar Mass General Hospital Disclosures Research
More informationCase. 63 year old woman now with:
Case 63 year old woman now with: HCV GT 1b, HCV RNA 6.2 x 10 6 IU/mL Asymptomatic except for fatigue Normal exam ALT 72 IU/mL, Bili 0.9 mg/dl, INR 1.1, Albumin 3.9 g/dl, Creatinine 0.7 mg/dl Normal EGD
More informationCurrent HCV Treatment by Genotype Empire Liver Foundation Ira M. Jacobson, MD
Current HCV Treatment by Genotype Empire Liver Foundation Ira M. Jacobson, MD Chairman, Department of Medicine Mount Sinai Beth Israel Professor of Medicine Co-Director, Liver Institute Icahn School of
More informationHCV: The next 18 months. David L. Wyles, M.D. Associate Professor of Medicine UCSD
HCV: The next 18 months David L. Wyles, M.D. Associate Professor of Medicine UCSD FIRST, A LOOK BACK WHAT DID I SAY LAST YEAR? My predictions for genotype 1: Multiple highly efficacious, well-tolerated,
More informationHepatitis C Virus: HIV/Hepatitis C Coinfection Wednesday, August 24, 2016
Hepatitis C Virus: HIV/Hepatitis C Coinfection Debika Bhattacharya, MD, MSc Associate Clinical Professor University of California Los Angeles Los Angeles, California Washington, DC: August 24, 2016 Slide
More informationWhy make this statement?
HCV Council 2014 10 clinical practice statements were evaluated by the Council A review of the available literature was conducted The level of support and level of evidence for the statements were discussed
More informationManagement of HIV/HCV Coinfection. Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY
Management of HIV/HCV Coinfection Kristen M. Marks, MD Assistant Professor Weill Cornell Medical College New York, NY Disclosure Dr. Marks has received grants and research support from Gilead Sciences
More informationManagement of Chronic HCV 2017 and Beyond
Management of Chronic HCV 2017 and Beyond Blaire E Burman, MD Virginia Mason Gastroenterology & Hepatology Relevant Disclosures No financial disclosures to report Leaning Objectives Burden of HCV Prevalence
More informationAASLD/IDSA HCV treatment guidelines. Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School
AASLD/IDSA HCV treatment guidelines Arthur Y. Kim, MD Massachusetts General Hospital Harvard Medical School Disclosure Statement for Arthur Kim Grant/research support to institution, last 12 months: Gilead
More informationHCV In 2015: Maximizing SVR
HCV In 2015: Maximizing SVR Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia ramji_a@hotmail.com Disclosures (within Last
More informationHepatitis C: Newest Treatment Options and What To Do When We Cure It!
Hepatitis C: Newest Treatment Options and What To Do When We Cure It! Richard Kalman, MD Division of Hepatology Department of Transplantation Einstein Medical Center Learning Objectives Scope of HCV How
More informationHepatitis C Difficult to Treat. Population. Disclosures
Hepatitis C Difficult to Treat Populations Paul Y Kwo MD Professor of Medicine Director of Hepatology Stanford University School of Medicine 75 Welch Road #21 Palo Alto, CA 9434 Disclosures Advisory Board
More informationSofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4
Phase 3 Treatment Experienced Sofosbuvir-Velpatasvir-Voxilaprevir in DAA-Experienced GT 1-6 POLARIS-4 Bourlière M, et al. N Engl J Med. 217;376:2134-46. POLARIS-4: Study Features POLARIS-4 Trial Design:
More informationRapid Response from San Francisco: The Latest in the HCV Treatment Revolution
Activity presentations are considered intellectual property. These slides may not be published or posted online without permission from Vindico Medical Education (cme@vindicocme.com). Please be respectful
More informationDo We Need New HCV Drugs? YES
Do We Need New HCV Drugs? YES Nancy Reau, MD Professor of Medicine Chief, Section of Hepatology Associate Director, Solid Organ Transplantation Rush University Medical Center Disclosures Consultation:
More informationHepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany
Hepatitis C: Difficult-to-treat Patients 11th Paris Hepatology Conference 16th January 2018 Stefan Zeuzem, MD University Hospital, Frankfurt, Germany PHC 2018 - www.aphc.info Disclosures Advisory boards:
More informationHepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection
Clinical Infectious Diseases IDSA FEATURES Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection AASLD-IDSA HCV Guidance Panel a (See
More informationLength of Authorization: 8-16 weeks. Requires PA: All direct-acting antivirals for treatment of Hepatitis C. Approval Criteria
Hepatitis C Direct-Acting Antivirals Goals: Approve use of cost-effective treatments supported by the medical evidence. Provide consistent patient evaluations across all hepatitis C treatments. Ensure
More informationFailure after treatment with DAAs: What to do? Marseille France 2-3 th June 2016
Failure after treatment with DAAs: What to do? Marc Bourliere, MD White Nights of Hepatology Hôpital Saint Joseph Saint Petersburg Marseille France 2-3 th June 16 Disclosures Board member for : Schering-Plough,
More informationHepatitis C Elimination: Screening, Linkage and Treatment. Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas
Hepatitis C Elimination: Screening, Linkage and Treatment Eric Lawitz, MD The Texas Liver Institute San Antonio, Texas Hepatitis C: Worldwide Presence Worldwide prevalence: 130-150 million Viral hepatitis
More informationSpecial developments in the management of Hepatitis C. Disclosures
Special developments in the management of Hepatitis C Sandeep Mukherjee,MD Division of Gastroenterology CHI Health and Creighton University Medical Center Omaha, NE 68154 Sandeep.Mukherjee@alegent.org
More informationThe Dawn of a New Era: Hepatitis C
The Dawn of a New Era: Hepatitis C Naudia L. Jonassaint Assistant Professor of Medicine and Surgery University Pittsburgh School of Medicine December 1, 2015 Objectives After presentation the learner should
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationHCV Screening, Management, and Treatment Guidelines
HCV ECHO WESTERN STATES HCV Screening, Management, and Treatment Guidelines Paulina Deming, PharmD, PhC Associate Professor of Pharmacy-College of Pharmacy Project ECHO University of New Mexico Health
More informationCase 4: A 61-year-old man with HCV genotype 3 with cirrhosis. Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA
Case 4: A 61-year-old man with HCV genotype 3 with cirrhosis Ira M. Jacobson, M.D. Weill Cornell Medical College New York, New York USA 1 Genotype 3 case 61-year-old man with HCV genotype 3 Cirrhosis on
More informationRome, February nd Riunione Annuale AISF th AISF ANNUAL MEETING
Rome, February 20-21 nd 2014 Riunione Annuale AISF 2014 14 th AISF ANNUAL MEETING Present and future treatment strategies for patients with HCV infection: chronic hepatitis and special populations IFN
More informationLearning Objective. After completing this educational activity, participants should be able to:
Learning Objective After completing this educational activity, participants should be able to: Use patient characteristics and preferences to select HCV treatment strategies that maximize the potential
More informationTreatments of Genotype 2, 3,and 4: Now and in the future
Treatments of Genotype 2, 3,and 4: Now and in the future THERAPY FOR THE TREATMENT OF GENOTYPE 2 1 GT 2 and GT 3 Treatment-Naïve: SOF+RBV vs PEG-IFN+RBV FISSION Study Design HCV GT 2 and GT 3 Treatment-naïve
More information